Cargando…
Hanshiyi Formula, a medicine for Sars-CoV2 infection in China, reduced the proportion of mild and moderate COVID-19 patients turning to severe status: A cohort study
We formulated a traditional Chinese medicine (TCM) prescription, Hanshiyi Formula (HSYF), which was approved and promoted by the Wuhan Municipal Health Commission for treating mild and moderate coronavirus disease 2019 (COVID-19). We aimed to evaluate the effect of HSYF on the progression to severe...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7416080/ https://www.ncbi.nlm.nih.gov/pubmed/32791263 http://dx.doi.org/10.1016/j.phrs.2020.105127 |
_version_ | 1783569256506458112 |
---|---|
author | Tian, Jiaxing Yan, Shiyan Wang, Han Zhang, Ying Zheng, Yujiao Wu, Haoran Li, Xiuyang Gao, Zezheng Ai, Yanke Gou, Xiaowen Zhang, Lei He, Liyun Lian, Fengmei Liu, Baoyan Tong, Xiaolin |
author_facet | Tian, Jiaxing Yan, Shiyan Wang, Han Zhang, Ying Zheng, Yujiao Wu, Haoran Li, Xiuyang Gao, Zezheng Ai, Yanke Gou, Xiaowen Zhang, Lei He, Liyun Lian, Fengmei Liu, Baoyan Tong, Xiaolin |
author_sort | Tian, Jiaxing |
collection | PubMed |
description | We formulated a traditional Chinese medicine (TCM) prescription, Hanshiyi Formula (HSYF), which was approved and promoted by the Wuhan Municipal Health Commission for treating mild and moderate coronavirus disease 2019 (COVID-19). We aimed to evaluate the effect of HSYF on the progression to severe disease in mild and moderate COVID-19 patients. We conducted a retrospective cohort study of patients with mild and moderate COVID-19 in a quarantine station in Wuchang District, Wuhan. Using the real-time Internet information collection application and Centers for Disease Control for the Wuchang District, patient data were collected through patient self-reports and follow-ups. HSYF intervention was defined as the exposure. The primary outcome was the proportion of patients who progressed to a severe disease status, and a stratification analysis was performed. Univariate and multivariate regression analyses were performed to identify influencing factors that may affect the outcome. Further, we used propensity score matching (PSM) to assess the effect of HSYF intervention on the conversion of mild and moderate to a severe disease status. Totally, 721 mild and moderate COVID-19 patients were enrolled, including 430 HSYF users (exposed group) and 291 non-users (control group). No cases in the exposed group and 19 (6.5 %, P < 0.001) cases in the control group progressed to severe disease, and the difference between the two groups (exposed group-control group) was −6.5 % [95 % confidence interval (CI): (−8.87 %, −4.13 %)]. Univariate regression analysis revealed sex (male), age, fever, cough, and fatigue as risk factors for progression to severe disease. After PSM, none of the HSYF users and 7 (4.7 %, P = 0.022) non-users transitioned to severe disease, and the difference between the two groups (exposed group-control group) was −4.7 % [95 % CI: (−8.2 %, −1.2 %)]. Multivariate regression analysis revealed that sex (male) [OR: 3.145; 95 % CI: 1.036–9.545; P = 0.043] and age (> 48 years) [odds ratio (OR): 1.044; 95 % CI: 1.001–1.088; P = 0.044] were independent risk factors for conversion to severe disease. Therefore, HSYF can significantly reduce the progression to severe disease in patients with mild and moderate COVID-19, which may effectively prevent and treat the disease. However, further larger clinical studies are required to verify our results. |
format | Online Article Text |
id | pubmed-7416080 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Elsevier Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-74160802020-08-10 Hanshiyi Formula, a medicine for Sars-CoV2 infection in China, reduced the proportion of mild and moderate COVID-19 patients turning to severe status: A cohort study Tian, Jiaxing Yan, Shiyan Wang, Han Zhang, Ying Zheng, Yujiao Wu, Haoran Li, Xiuyang Gao, Zezheng Ai, Yanke Gou, Xiaowen Zhang, Lei He, Liyun Lian, Fengmei Liu, Baoyan Tong, Xiaolin Pharmacol Res Article We formulated a traditional Chinese medicine (TCM) prescription, Hanshiyi Formula (HSYF), which was approved and promoted by the Wuhan Municipal Health Commission for treating mild and moderate coronavirus disease 2019 (COVID-19). We aimed to evaluate the effect of HSYF on the progression to severe disease in mild and moderate COVID-19 patients. We conducted a retrospective cohort study of patients with mild and moderate COVID-19 in a quarantine station in Wuchang District, Wuhan. Using the real-time Internet information collection application and Centers for Disease Control for the Wuchang District, patient data were collected through patient self-reports and follow-ups. HSYF intervention was defined as the exposure. The primary outcome was the proportion of patients who progressed to a severe disease status, and a stratification analysis was performed. Univariate and multivariate regression analyses were performed to identify influencing factors that may affect the outcome. Further, we used propensity score matching (PSM) to assess the effect of HSYF intervention on the conversion of mild and moderate to a severe disease status. Totally, 721 mild and moderate COVID-19 patients were enrolled, including 430 HSYF users (exposed group) and 291 non-users (control group). No cases in the exposed group and 19 (6.5 %, P < 0.001) cases in the control group progressed to severe disease, and the difference between the two groups (exposed group-control group) was −6.5 % [95 % confidence interval (CI): (−8.87 %, −4.13 %)]. Univariate regression analysis revealed sex (male), age, fever, cough, and fatigue as risk factors for progression to severe disease. After PSM, none of the HSYF users and 7 (4.7 %, P = 0.022) non-users transitioned to severe disease, and the difference between the two groups (exposed group-control group) was −4.7 % [95 % CI: (−8.2 %, −1.2 %)]. Multivariate regression analysis revealed that sex (male) [OR: 3.145; 95 % CI: 1.036–9.545; P = 0.043] and age (> 48 years) [odds ratio (OR): 1.044; 95 % CI: 1.001–1.088; P = 0.044] were independent risk factors for conversion to severe disease. Therefore, HSYF can significantly reduce the progression to severe disease in patients with mild and moderate COVID-19, which may effectively prevent and treat the disease. However, further larger clinical studies are required to verify our results. Elsevier Ltd. 2020-11 2020-08-10 /pmc/articles/PMC7416080/ /pubmed/32791263 http://dx.doi.org/10.1016/j.phrs.2020.105127 Text en © 2020 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Tian, Jiaxing Yan, Shiyan Wang, Han Zhang, Ying Zheng, Yujiao Wu, Haoran Li, Xiuyang Gao, Zezheng Ai, Yanke Gou, Xiaowen Zhang, Lei He, Liyun Lian, Fengmei Liu, Baoyan Tong, Xiaolin Hanshiyi Formula, a medicine for Sars-CoV2 infection in China, reduced the proportion of mild and moderate COVID-19 patients turning to severe status: A cohort study |
title | Hanshiyi Formula, a medicine for Sars-CoV2 infection in China, reduced the proportion of mild and moderate COVID-19 patients turning to severe status: A cohort study |
title_full | Hanshiyi Formula, a medicine for Sars-CoV2 infection in China, reduced the proportion of mild and moderate COVID-19 patients turning to severe status: A cohort study |
title_fullStr | Hanshiyi Formula, a medicine for Sars-CoV2 infection in China, reduced the proportion of mild and moderate COVID-19 patients turning to severe status: A cohort study |
title_full_unstemmed | Hanshiyi Formula, a medicine for Sars-CoV2 infection in China, reduced the proportion of mild and moderate COVID-19 patients turning to severe status: A cohort study |
title_short | Hanshiyi Formula, a medicine for Sars-CoV2 infection in China, reduced the proportion of mild and moderate COVID-19 patients turning to severe status: A cohort study |
title_sort | hanshiyi formula, a medicine for sars-cov2 infection in china, reduced the proportion of mild and moderate covid-19 patients turning to severe status: a cohort study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7416080/ https://www.ncbi.nlm.nih.gov/pubmed/32791263 http://dx.doi.org/10.1016/j.phrs.2020.105127 |
work_keys_str_mv | AT tianjiaxing hanshiyiformulaamedicineforsarscov2infectioninchinareducedtheproportionofmildandmoderatecovid19patientsturningtoseverestatusacohortstudy AT yanshiyan hanshiyiformulaamedicineforsarscov2infectioninchinareducedtheproportionofmildandmoderatecovid19patientsturningtoseverestatusacohortstudy AT wanghan hanshiyiformulaamedicineforsarscov2infectioninchinareducedtheproportionofmildandmoderatecovid19patientsturningtoseverestatusacohortstudy AT zhangying hanshiyiformulaamedicineforsarscov2infectioninchinareducedtheproportionofmildandmoderatecovid19patientsturningtoseverestatusacohortstudy AT zhengyujiao hanshiyiformulaamedicineforsarscov2infectioninchinareducedtheproportionofmildandmoderatecovid19patientsturningtoseverestatusacohortstudy AT wuhaoran hanshiyiformulaamedicineforsarscov2infectioninchinareducedtheproportionofmildandmoderatecovid19patientsturningtoseverestatusacohortstudy AT lixiuyang hanshiyiformulaamedicineforsarscov2infectioninchinareducedtheproportionofmildandmoderatecovid19patientsturningtoseverestatusacohortstudy AT gaozezheng hanshiyiformulaamedicineforsarscov2infectioninchinareducedtheproportionofmildandmoderatecovid19patientsturningtoseverestatusacohortstudy AT aiyanke hanshiyiformulaamedicineforsarscov2infectioninchinareducedtheproportionofmildandmoderatecovid19patientsturningtoseverestatusacohortstudy AT gouxiaowen hanshiyiformulaamedicineforsarscov2infectioninchinareducedtheproportionofmildandmoderatecovid19patientsturningtoseverestatusacohortstudy AT zhanglei hanshiyiformulaamedicineforsarscov2infectioninchinareducedtheproportionofmildandmoderatecovid19patientsturningtoseverestatusacohortstudy AT heliyun hanshiyiformulaamedicineforsarscov2infectioninchinareducedtheproportionofmildandmoderatecovid19patientsturningtoseverestatusacohortstudy AT lianfengmei hanshiyiformulaamedicineforsarscov2infectioninchinareducedtheproportionofmildandmoderatecovid19patientsturningtoseverestatusacohortstudy AT liubaoyan hanshiyiformulaamedicineforsarscov2infectioninchinareducedtheproportionofmildandmoderatecovid19patientsturningtoseverestatusacohortstudy AT tongxiaolin hanshiyiformulaamedicineforsarscov2infectioninchinareducedtheproportionofmildandmoderatecovid19patientsturningtoseverestatusacohortstudy |